Dr.Singh accomplished his doctorate in biochemistry from South Campus Delhi University, New Delhi, India. Dr Singh is a proficient molecular biologist and biochemist with a core specialization in mRNA therapeutics, antibody engineering, phage display, and next-generation sequencing.

Dr Singh is part of Gennova since 2013 and has widened his horizon by working on various domains. His heart of research at Gennova is mRNA vaccines, therapeutics, antibody engineering, production and localization studies. Dr Singh is known for his notable contribution in the area of mRNA vaccine designing, development and production by creating keener genetic designs, versatile and robust mRNA production processes. From the first moments of the COVID-19 pandemic, he is working diligently for the development of the first fully indigenous mRNA vaccine in India. His group of astute scientists has also made advances addressing the SARS-CoV-2 variants through the next era of vaccinology and mRNA vaccines.

Graduated from Department of Life Sciences, POSTECH, Korea in 2002 with a PhD, Prof Kim Yoon Ki has contributed to over 80 publications. He is currently a director in the creative research initiatives center and also an assistant, associate and full professor from Division of Life Sciences, Korea University. His current research work in his laboratory focuses on the regulation of gene expression via mRNA stability and translation in mammalian cells.

Nam-Joon Cho is Nanyang Associate Professor in the School of Materials Science and Engineering at Nanyang Technological University in Singapore and Deputy Director of the Nanyang Institute of Technology in Health and Medicine. In addition, he is a Materials Research Society of Singapore Chair Professor and Principal Investigator at the Singapore-MIT Alliance for Research and Technology. His group’s research focuses on engineering approaches to solve important biomedical problems and to translate these capabilities into practical applications for global health. Dr. Cho’s scientific work has been highlighted by international media organizations such as Reuters, CNBC, and Businessweek, and is leading to major breakthroughs for the treatment of deadly pathogens. He has identified novel classes of antiviral drugs to treat hepatitis C and dengue virus infections. Dr. Cho’s team is now actively working to examine the causes and consequences of infectious diseases in order to provide improved diagnostic and therapeutic interventions. Dr. Cho also leads a multi-institution tissue engineering collaboration involving NTU and the Stanford University School of Medicine, which focuses on developing an artificial liver platform for regenerative medicine applications. He is a graduate of Stanford University and the University of California, Berkeley.

Bhawana is International Product Manager responsible for mRNA product portfolio of CustomBiotech business. Prior to joining Roche, Bhawana held various positions in sales and global marketing at QIAGEN GmbH, Germany. Bhawana holds a PhD in Cardiovascular disease from Imperial College London and a Bachelor’s degree in Biochemistry and Cell Biology from Jacobs University Bremen, Germany.

Brandon Yeow has been an APAC regional account manager at Roche Diagnostics since 2017. He graduated from University of Western Australia in 2016. Since then he has been involved in sales and marketing for Roche CustomBiotech which focuses on supplying raw materials for biopharmaceutical and diagnostic manufacturers. He is also a keen learner about new technologies for both market segments.